ID26743A - Turunan 1,2,4,5-tetrahidro-benzo [d] azepin - Google Patents

Turunan 1,2,4,5-tetrahidro-benzo [d] azepin

Info

Publication number
ID26743A
ID26743A IDP20000655A ID20000655A ID26743A ID 26743 A ID26743 A ID 26743A ID P20000655 A IDP20000655 A ID P20000655A ID 20000655 A ID20000655 A ID 20000655A ID 26743 A ID26743 A ID 26743A
Authority
ID
Indonesia
Prior art keywords
tetrahidro
azepin
benzo
during
Prior art date
Application number
IDP20000655A
Other languages
English (en)
Inventor
Geo Adam
Alfred Binggeli
Hans-Peter Marki
Vincent Mutel
Maurice Wilhelm
Wolfgang Wostl
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of ID26743A publication Critical patent/ID26743A/id

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
IDP20000655A 1999-08-06 2000-08-02 Turunan 1,2,4,5-tetrahidro-benzo [d] azepin ID26743A (id)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP99115557 1999-08-06

Publications (1)

Publication Number Publication Date
ID26743A true ID26743A (id) 2001-02-08

Family

ID=8238742

Family Applications (1)

Application Number Title Priority Date Filing Date
IDP20000655A ID26743A (id) 1999-08-06 2000-08-02 Turunan 1,2,4,5-tetrahidro-benzo [d] azepin

Country Status (27)

Country Link
US (1) US6218385B1 (id)
JP (1) JP3260350B2 (id)
KR (1) KR100390116B1 (id)
CN (1) CN1146455C (id)
AR (1) AR025035A1 (id)
AT (1) ATE254614T1 (id)
AU (1) AU774485B2 (id)
BR (1) BR0003375A (id)
CA (1) CA2314798A1 (id)
CO (1) CO5180625A1 (id)
DE (1) DE60006618T2 (id)
ES (1) ES2209728T3 (id)
HR (1) HRP20000520A2 (id)
HU (1) HUP0003112A3 (id)
ID (1) ID26743A (id)
IL (1) IL137688A0 (id)
MA (1) MA26748A1 (id)
NO (1) NO20003966L (id)
NZ (1) NZ506096A (id)
PE (1) PE20010467A1 (id)
PL (1) PL341890A1 (id)
RU (1) RU2240317C2 (id)
SG (1) SG93251A1 (id)
TR (1) TR200002298A2 (id)
UY (1) UY26276A1 (id)
YU (1) YU49700A (id)
ZA (1) ZA200003927B (id)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2432077C (en) * 2000-12-22 2011-01-18 F. Hoffmann-La Roche Ag Tetrahydro-(benzo or thieno)-azepine-pyrazine and triazine derivatives as mglur 1 antagonists
US6953787B2 (en) 2002-04-12 2005-10-11 Arena Pharmaceuticals, Inc. 5HT2C receptor modulators
CA2509413C (en) * 2002-12-20 2012-05-01 Glaxo Group Limited Benzazepine derivatives for the treatment of neurological disorders
CN1805938B (zh) * 2003-06-17 2010-06-16 艾尼纳制药公司 用于治疗5ht2c受体相关疾病的苯并氮杂卓衍生物
EP2332919A3 (en) * 2003-06-17 2011-10-19 Arena Pharmaceuticals, Inc. Processes for preparing 3-benzazepines
US20070275949A1 (en) * 2003-10-22 2007-11-29 Arena Pharmaceuticals, Inc. Benzazepine Derivatives and Methods of Prophylaxis or Treatment of 5Ht2C Receptor Associated Diseases
WO2005042491A1 (en) * 2003-10-22 2005-05-12 Arena Pharmaceuticals, Inc. Benzazepine derivatives and methods of prophylaxis or treatment of 5ht2c receptor associated diseases
DK1838677T3 (da) 2004-12-21 2010-01-11 Arena Pharm Inc Krystallinske former af (R)-8-chlor-1.methyl-2,3,4,5-tetrahydro-1H-3-benzazepinhydrochlorid
CN102627607A (zh) * 2004-12-23 2012-08-08 艾尼纳制药公司 5HT2c受体调节剂组合物和使用方法
EP2258358A3 (en) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
EP2275095A3 (en) 2005-08-26 2011-08-17 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
JP2009512711A (ja) 2005-10-21 2009-03-26 ブレインセルス，インコーポレイティド Ｐｄｅ阻害による神経新生の調節
CA2625210A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
CA2646044A1 (en) 2006-04-03 2007-10-25 Arena Pharmaceuticals, Inc. Processes for the preparation of 8-chloro-1-methyl-2,3,4,5-tetrahydro-1h-3-benzazepine and intermediates related thereto
WO2007134136A2 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
AU2007249435A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. 5 HT receptor mediated neurogenesis
EP1873527A1 (en) * 2006-06-30 2008-01-02 Schwarz Pharma Ag Method for identifying CRMP modulators
KR20090064418A (ko) 2006-09-08 2009-06-18 브레인셀즈 인코퍼레이션 4-아실아미노피리딘 유도체 포함 조합물
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
LT2083811T (lt) 2006-11-22 2017-01-25 Clinical Research Associates, Llc Dauno sindromo, trapiosios x chromosomos sindromo ir autizmo gydymo būdai
WO2008070111A2 (en) * 2006-12-05 2008-06-12 Arena Pharmaceuticals, Inc. Processes for preparing (r)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1h-3-benzazepine and intermediates thereof
TW200845978A (en) * 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
EP2288585A1 (en) 2008-03-04 2011-03-02 Arena Pharmaceuticals, Inc. Processes for the preparation of intermediates related to the 5-ht2c agonist (r)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1h-3-benzazepine
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
WO2010148207A2 (en) 2009-06-18 2010-12-23 Arena Pharmaceuticals, Inc. Processes for the preparation of 5-ht2c receptor agonists
EP2544688B1 (en) 2010-03-02 2016-09-07 President and Fellows of Harvard College Methods and compositions for treatment of angelman syndrome
WO2011150380A1 (en) 2010-05-28 2011-12-01 Xenoport, Inc. Methods of treatment of fragile x syndrome, down's syndrome, autism and related disorders
US9045431B2 (en) 2010-06-02 2015-06-02 Arena Pharmaceuticals, Inc. Processes for the preparation of 5-HT2C receptor agonists
US20120016021A1 (en) 2010-07-15 2012-01-19 Xenoport, Inc. Methods of treating fragile x syndrome, down's syndrome, autism and related disorders
US9365521B2 (en) 2010-09-01 2016-06-14 Arena Pharmaceuticals, Inc. Non-hygroscopic salts of 5-HT2C agonists
SG10201506874UA (en) 2010-09-01 2015-10-29 Arena Pharm Inc Modified-release dosage forms of 5-ht2c agonists useful for weight management
JP2013539470A (ja) 2010-09-01 2013-10-24 アリーナ ファーマシューティカルズ， インコーポレイテッド ロルカセリンと光学活性な酸との塩
KR20180094131A (ko) 2010-09-01 2018-08-22 에자이 알앤드디 매니지먼트 가부시키가이샤 신장 손상을 갖는 개체에 대한 로카세린의 투여
MX2015004532A (es) 2012-10-09 2016-01-20 Arena Pharm Inc Metodo de control del peso.

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4206210A (en) * 1977-01-19 1980-06-03 Smithkline Corporation Alkylthio-7,8-dihdroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepines having dopaminergic activity
KR930702292A (ko) * 1990-11-06 1993-09-08 알렌 제이. 스피겔 종양 치료 활성을 증대시키기 위한 퀴나졸린 유도체
US5241065A (en) * 1992-02-25 1993-08-31 Schering Corporation 2,3,4,5-tetrahydro-1h-3-benzazepines having anti-psychotic activity

Also Published As

Publication number Publication date
HUP0003112A2 (hu) 2002-11-28
AR025035A1 (es) 2002-11-06
PE20010467A1 (es) 2001-04-17
JP2001089472A (ja) 2001-04-03
PL341890A1 (en) 2001-02-12
US6218385B1 (en) 2001-04-17
NZ506096A (en) 2002-08-28
KR100390116B1 (ko) 2003-07-04
ATE254614T1 (de) 2003-12-15
NO20003966L (no) 2001-02-07
ZA200003927B (en) 2001-02-06
AU774485B2 (en) 2004-07-01
DE60006618T2 (de) 2004-09-23
BR0003375A (pt) 2001-03-13
RU2240317C2 (ru) 2004-11-20
HUP0003112A3 (en) 2003-07-28
HU0003112D0 (en) 2000-10-28
KR20010082510A (ko) 2001-08-30
CO5180625A1 (es) 2002-07-30
DE60006618D1 (de) 2003-12-24
JP3260350B2 (ja) 2002-02-25
YU49700A (sh) 2003-04-30
MA26748A1 (fr) 2004-12-20
AU4897900A (en) 2001-02-08
SG93251A1 (en) 2002-12-17
HRP20000520A2 (en) 2001-06-30
TR200002298A3 (tr) 2001-03-21
CN1146455C (zh) 2004-04-21
TR200002298A2 (tr) 2001-03-21
CA2314798A1 (en) 2001-02-06
IL137688A0 (en) 2001-10-31
UY26276A1 (es) 2000-10-31
NO20003966D0 (no) 2000-08-04
ES2209728T3 (es) 2004-07-01
CN1283623A (zh) 2001-02-14

Similar Documents

Publication Publication Date Title
ID26743A (id) Turunan 1,2,4,5-tetrahidro-benzo [d] azepin
DE69933287D1 (de) 12,13-modifizierte epothilon-derivate
MA26831A1 (fr) Derives de benzodiazepine."
ID29241A (id) Turunan-turunan kinolin teranelasi-1,2
ZA200000894B (en) 4-Phenyl-pyridine derivatives.
DE60019577D1 (de) 4, 5, 6, 7-tetrahydroindazolderivate als antitumormittel
HK1046411A1 (en) 5-Phenyl-pyrimidine derivatives.
IL149584A0 (en) New phenalkyloxy-phenyl derivatives
EG23070A (en) Novel propargylether derivatives
ID28483A (id) 2-(3,5-bis-trifluorometil-fenil)-metil-n-(6-morfolin-4-il-4-0-tolil-piridin-3-il)-isobutiramida
EE04089B1 (et) 1,3,4-oksadiasolooni derivaadid
DE60025958D1 (de) 14,15-beta-methylen substituierte androgene
ID27686A (id) Turunan 3-(2-okso-[1,3]bipirolidinil-3-ildenametil)-sefem
DK1149106T3 (da) 4,5-azolo-oxindoler
HUP0204217A3 (en) Novel a-500359 derivatives
MXPA01011285A (es) Derivados de tio-oxindol.
HUP9902291A2 (hu) Új 2,3-benzodiazepin-származékok
NO20015397L (no) 1,5-Benzodiazepin-derivater
GB2350361B (en) 3,4,5-tricyanophenyl derivatives
ES1042496Y (es) "pilona sumible".
FR2797145B1 (fr) Machine desileuse-melangeuse-distributrice perfectionnee
GB9923759D0 (en) Dyes
IL165436A0 (en) 7,10-bis-trichlotoacetyl-10 deactylbaccatin III
ZA200203703B (en) New Phenalkyloxy-phenyl derivatives.
FI980405A0 (fi) Industriellt, kontinuerligt foerfarande foer framstaellning av "gravkalk"